Eyeing a bigger share of India’s fast growing anti-obesity drug market pie, Danish pharma major Novo Nordisk has slashed the price of Wegovy by up to 37%.
With this, the drugmaker is seeking to take on key rival Eli Lilly, which has seen brisk sales of Mounjaro ever since it was launched in India in March this year.
Wegovy vs Mounjaro: How much the weight loss drugs cost
According to the news agency Reuters, the monthly price for Wegovy’s highest dose of 2.4 mg will now cost 16,400 rupees ($186.59), compared with its earlier price of 24,389.06 rupees. Its lowest dose of 0.25 mg will now be available at Rs 10,850 for a monthly pack, compared with Rs 16,260.94 rupees earlier.
Rival Mounjaro‘s single-dose vial costs between Rs 14,000 to Rs 17,500 monthly, while its easy-to-use KwikPen, the 15 mg dose is available at the cost of Rs 27,500 per month, according to an Indian Express report.
Mounjaro’s sales skyrocket in India
Meanwhile, Mounjaro has been the top-selling drug in India reporting sales of Rs 100 cr in October, per market research firm Pharmarack.
“We have made sure to listen to our patient and doctor communities and take active measures for the benefit of people at large,” Vikrant Shrotriya, managing director, Novo Nordisk India, told Reuters.
Wegovy that launched in June, is trying to catch up with the sales of Mounjaro that entered the Indian market in March and doubled its sales within months of its launch.
Wegovy vs Mounjaro: Which works better for weight loss?
The GLP-1 drugs work by mimicking the function of hormone glucagon-like peptide 1 that helps lower blood sugar levels and promote weight loss, as per Cleveland Clinic. They promote a longer-lasting feeling of fullness and are prescribed for obesity and diabetes.
Wegovy’s active ingredient semaglutide goes off patent in India in March 2026, paving the way for generic drugmakers to enter the market.
According to studies, Mounjaro with the active ingredient tirzepatide resulted in greater weight loss compared to Wegovy.
A study published in JAMA Internal Medicine Medical Journal found that people taking tirzepatide (Mounjaro) injections lost more weight and were more likely to reach specific weight loss targets compared to those taking semaglutide.
